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SObjectives: Women with lung cancer have superior long-term survival outcomes compared with men,
independent of stage. The cause of this disparity is unknown. For patients undergoing lung cancer resection,
these survival differences could be due, in part, to relatively better perioperative outcomes for women. This study
was undertaken to determine differences in perioperative outcomes after lung cancer surgery on the basis of sex.
Methods: The Society of Thoracic Surgeons’ General Thoracic Database was queried for all patients undergo-
ing resection of lung cancer between 2002 and 2010. Postoperative complications were analyzed with respect to
sex. Univariable analysis was performed, followed by multivariable modeling to determine significant risk fac-
tors for postoperative morbidity and mortality.
Results: A total of 34,188 patients (16,643 men and 17,545 women) were considered. Univariable analysis
demonstrated statistically significant differences in postoperative complications favoring women in all
categories of postoperative complications. Women also had lower in-hospital and 30-day mortality (odds ratio,
0.56; 95% confidence interval, 0.44-0.71; P < .001). Multivariable analysis demonstrated that several
preoperative conditions independently predicted 30-day mortality: male sex, increasing age, lower diffusion
capacity, renal insufficiency, preoperative radiation therapy, cancer stage, extent of resection, and thoracotomy
as surgical approach. Coronary artery diseasewas an independent predictor ofmortality inwomen but not inmen.
Thoracotomy as the surgical approach and preoperative radiation therapy were predictive of mortality for men
but not for women. Postoperative prolonged air leak and empyema predicted mortality in men but not in women.
Conclusions: Women have lower postoperative morbidity and mortality after lung cancer surgery. Some risk
factors are sex-specific with regard to mortality. Further study is warranted to determine the cause of these
differences and to determine their effect on survival. (J Thorac Cardiovasc Surg 2014;148:13-8)Earn CME credits at
http://jtcvs.com/cme/home
Lung cancer is the leading cause of cancer mortality for both
men and women.1 Several studies have demonstrated sex
differences in the epidemiology, clinical presentation, tumor
biology, and survival from lung cancer. Comparedwithmen,
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The Journal of Thoracic and Cyounger age.2 Women also appear to be more susceptible to
the carcinogenic effects of cigarette smoke.3 In addition,
women are more likely to be diagnosed with advanced-
stage disease, and nonsmokers diagnosed with lung cancer
also are more likely to be women.4
Many studies have shown a survival advantage for
women regarding lung cancer prognosis and survival.
These differences persist regardless of stage or treatment
modality.5-7 For patients with early-stage disease undergo-
ing surgical resection, there is a relative paucity of data
describing any association between perioperative outcomes
and long-term survival with non–small cell lung cancer. It is
possible that patients with better perioperative outcomes
may have improved long-term survival outcomes, due to
factors such as increased adherence to adjuvant therapy
regimens.
Several studies have consistently identified male sex as a
poor prognostic factor in predicting prolonged length
of hospital stay and perioperative mortality, as well as
long-term survival.8-11 By using the Society of Thoracic
Surgeons (STS) General Thoracic Database, we sought to
further examine sex differences in perioperative outcomes
after lung cancer resection in a large cohort and toardiovascular Surgery c Volume 148, Number 1 13
Abbreviations and Acronyms
DLCO ¼ diffusion capacity of carbon monoxide
FEV1 ¼ forced expiratory volume in 1 second
STS ¼ Society of Thoracic Surgeons
General Thoracic Surgery Tong et al
G
T
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mortality differed between men and women.METHODS
Data Source and Study Cohort
The STS Database Access and Publications Committee and the
Institutional Review Board of the Duke University Medical Center
approved this study. The STS General Thoracic Database was queried
for all patients undergoing resection for lung cancer between 2002 and
2010. Patients aged less than 18 years or undergoing lung resection for
non–lung cancer diagnoses were excluded from the analysis.Variables
Demographic information (age, sex), pulmonary function, preoperative
comorbid conditions, extent of resection, surgical approach, and pathologic
stage were examined. Comorbid conditions included coronary artery
disease, diabetes, history of chemotherapy or radiation, and renal
insufficiency. Procedures examined included wedge resection (single or
multiple), segmentectomy, lobectomy, bilobectomy, sleeve lobectomy,
and pneumonectomy. For purposes of the analysis, procedures were
grouped into sublobar (wedge, segmentectomy), lobar (lobectomy, sleeve
lobectomy, thoracoscopic lobectomy), and greater-than-lobar resections
(bilobectomy, completion pneumonectomy, standard and carinal
pneumonectomy). Postoperative events considered were those identified
on the Data Collection Form of the STS General Thoracic Surgery
Database (http://www.sts.org/quality-research-patient-safety/national-data
base/database-managers/general-thoracic-surgery-databa-1).
Statistical Analysis
Fisher exact test was used to determine whether sex was predictive of
postoperative complications in the selected population. Association with
sex for continuous variables was tested with 2-sample Wilcoxon test and
for categoric variables with the Fisher exact test. In addition to 30-day or
discharge mortality, individual postoperative events as defined on the
database data-collection form were used in the univariable model.
A logistic regression model was used to identify predictors of mortality
after surgery, as defined by the STS General Thoracic Database form:
immediately postoperatively to discharge, if discharge occurred more
than 30 days after procedure, or immediately postoperatively, up to 30
days, if discharged before that time. This model was then applied to the
male and female portions of the cohort separately to identify sex-specific
risk factors for perioperative mortality. Only patients with complete data
were considered for the multivariable model; if at least 1 covariate or
outcome was missing, the patient was excluded from the analysis. For
the multivariable model, the individual events were grouped into categories
for ease of the analysis. The following categories were considered: 30-day
or discharge mortality; pulmonary complications (postoperative air leak
>5 days, atelectasis requiring bronchoscopy, pneumonia, evidence of adult
respiratory distress syndrome, bronchopleural fistula, reintubation,
pulmonary embolus or deep venous thrombosis requiring treatment, initial
ventilator support>48 hours, tracheostomy, or other pulmonary event);
cardiovascular complications (atrial or ventricular arrhythmia, myocardial
infarction, other cardiovascular event); gastrointestinal complications;
hematologic complications (bleeding requiring reoperation, postoperative14 The Journal of Thoracic and Cardiovascular Surgeblood transfusion); infectious complications (urinary tract infection,
empyema, wound infection, septicemia, or other infection requiring
treatment); neurologic complications (new central neurologic event, recur-
rent laryngeal nerve paresis, delirium tremens, or other neurologic event);
and miscellaneous complications (new or worsening renal failure,
chylothorax, other events requiring medical treatment or other events
requiring operating with general anesthesia or unexpected admission to
intensive care unit). The analysis was conducted using SAS statistical
package version 9.2 (SAS Institute, Cary, NC) and R version 2.8.1 package
(http://www.R-project.org).RESULTS
Between 2002 and 2010, a total of 34,188 patients
(17,545 female and 16,643 male) underwent resection for
lung cancer in the STS General Thoracic Surgery Database.
Women and men differed with regard to baseline
characteristics and comorbid conditions (Table 1). Women
were younger at the time of surgery with a mean age of
65.8 years, compared with 67.0 years for men (P<.001).
Although the mean forced expiratory volume in 1 second
(FEV1) was significantly higher for women compared
with men (80.4% predicted vs 75.4% predicted, respec-
tively, P<.001), the diffusion capacity of carbon monoxide
(DLCO) was significantly lower (69.7% predicted for
women vs 72.7% for men, P < .001). With regard to
preoperative comorbid conditions, a significantly higher
proportion of men had a history of diabetes, coronary artery
disease, and renal insufficiency compared with women.
In contrast, significantly more women than men had
undergone chemotherapy or radiation before surgery. There
was a difference in pathologic stage distribution between
genders (P< .001), with a higher proportion of women
having pathologic stage I disease, relative to higher stages,
compared with men. Although the majority of both groups
underwent lobectomy for lung cancer resection, women had
a relatively higher proportion of sublobar resection and
relatively lower proportion of greater-than-lobar resection
for surgery, compared with men (P<.001).
Of the 34,188 patients in the study cohort, there were
751 total deaths within 30 days or at discharge (2.2%).
However, the mortality rates differed between men and
women (Table 2). In female patients, 259 of 17,545
(1.5%) died; in male patients, 492 of 16,643 (3.0%) died
(P<.001).
In univariable models of individual postoperative compli-
cations, sex was a significant predictor in nearly all events
examined. This included each of the individual events
within the pulmonary, cardiac, neurologic, hematologic, in-
fectious, and gastrointestinal categories. Female sexwas not
significant in predicting postoperative chylothorax, either
managed medically or requiring surgical intervention
(P ¼ .41 and P ¼ .11, respectively). Despite the increased
frequency of postoperative complications in men, there
was no difference in the proportions of patients who dis-
charged to a site other than home (eg, nursing home).ry c July 2014
TABLE 1. Sex differences in baseline and operative characteristics
Characteristic Female (%) N ¼ 17,545 (51.3) Male (%) N ¼ 16,643 (48.7) Total (%) P value
Age (y), mean (SD) 65.8 (11.2) 67.0 (10.7) 66.4 (10.9) <.001
FEV1 predicted, mean (SD) 80.4 (23.1) 75.4 (22.7) 78.0 (23.0) <.001
DLCO predicted, mean (SD) 69.7 (22.8) 72.7 (24.0) 71.2 (23.4) <.001
Diabetes mellitus 2258 (13.2) 3003 (18.5) 5261 (15.8) <.001
Coronary artery disease 2271 (15.4) 4786 (32.9) 7057 (24.0) <.001
Preoperative chemotherapy 2174 (14.7) 1986 (13.7) 4160 (14.2) .013
Preoperative radiation therapy 1637 (11.1) 1426 (9.8) 3063 (10.5) <.001
Renal insufficiency 262 (1.6) 518 (3.3) 780 (2.4) <.001
Pathologic stage <.001
I 9648 (69.5) 8610 (65.1) 18,258 (67.3)
II 1886 (13.6) 2264 (17.1) 4150 (15.3)
III 1893 (13.6) 1885 (14.2) 3778 (13.9)
IV 454 (3.3) 475 (3.6) 929 (3.4)
Extent of resection <.001
Sublobar 3713 (21.2) 3226 (19.4) 6939 (20.3)
Lobar 12,682 (72.3) 11,718 (70.4) 24,400 (71.4)
>Lobar 1150 (6.6) 1699 (10.2) 2849 (8.3)
Surgical approach <.001
Open 11,309 (66.2) 11,622 (72.0) 22,931 (69.0)
VATS 5772 (33.8) 4517 (28.0) 10,289 (31.0)
DLCO, Diffusion capacity of carbon monoxide; FEV1, forced expiratory volume in 1 second; SD, standard deviation; VATS, video-assisted thoracic surgery.
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(7823 female and 7706 male) had no missing data for vari-
ables considered in the final multivariable model
of discharge or 30-day mortality. Among all patients, signif-
icant predictors of mortality included male sex, increasing
age, decreasing DLCO, preoperative radiation therapy,
renal insufficiency, higher pathologic stage, greater extent
of resection, open thoracotomy, and postoperative empy-
ema requiring treatment (Table 3). When the groups were
separated by sex, the independent predictors of mortality
differed. Age, DLCO, renal insufficiency, and pathologic
stagewere predictive in the separated groups. However, cor-
onary artery disease was predictive of mortality in women
but not in men (P<.001). Likewise, preoperative radiation
therapy (P< .001), thoracotomy as the surgical approach
(P< .001), postoperative prolonged air leak (P ¼ .02),
and empyema (P ¼ .004) all were predictive of mortality
in men but not in women.
DISCUSSION
This study demonstrates that women and men
undergoing surgery for lung cancer differ with regard to
preoperative characteristics and comorbidities. At baseline,
women are younger and seem to be healthier than their male
counterparts, because a significantly smaller proportion
of female patients reported a history of coronary artery
disease, renal insufficiency, and diabetes. In addition, there
are sex-specific predictors of perioperative mortality for
patients undergoing lung cancer resection. To our
knowledge, this is the first study to identify such predictors
for the female and male patient populations.The Journal of Thoracic and CMore men than women in the study cohort underwent bi-
lobectomy, sleeve resection, or pneumonectomy. There is
relatively higher morbidity and mortality associated with
these procedures compared with standard lobectomy and
sublobar resection. The relatively higher proportion of these
procedures in men may contribute to the increased periop-
erative mortality seen in the study. Also, a relatively higher
proportion of female patients had stage I disease. Patients
with stage I disease have a better overall prognosis, and
those who avoid adjuvant therapy also avoid the toxicities
associated with chemotherapy and radiation.
Of note, despite the fact that women had more stage I dis-
ease than men, a higher proportion of women had a history
of preoperative radiation and chemotherapy. Although the
STS General Thoracic Database form delineates both the
time course and the indication for preoperative chemo-
therapy and radiation therapy, we did not separate these fac-
tors in the analysis becausemorewomen had stage I disease,
and thus would be less likely to have undergone preopera-
tive chemotherapy and radiation therapy for their lung can-
cer. We can only conclude that the women reporting a
history of preoperative chemotherapy and radiation therapy
received it for a different indication, such as breast cancer.
These data also confirm that women undergoing lung
cancer resection have decreased rates of postoperative
morbidity and mortality after lung cancer resection. In
nearly every category of postoperative complication as
defined in the STS Database, women had lower morbidity
compared with men. Furthermore, some predictors of
perioperative morbidity and mortality differ among men
and women.ardiovascular Surgery c Volume 148, Number 1 15
TABLE 2. Sex differences in postoperative complications
Postoperative event Female (%) N ¼ 17,545 Male (%) N ¼ 16,643 P value
Discharge or 30-d mortality 259 (1.5) 492 (3.0) <.001
Air leak with duration>5 d 1387 (7.9) 1660 (10.0) <.001
Atelectasis requiring bronchoscopy 522 (3.0) 686 (4.1) <.001
Pneumonia 537 (3.1) 800 (4.8) <.001
Evidence of adult respiratory distress syndrome 153 (0.9) 227 (1.4) <.001
Bronchopleural fistula 46 (0.3) 93 (0.6) <.001
Reintubation 512 (2.9) 742 (4.5) <.001
Pulmonary embolus or DVT requiring treatment 129 (0.7) 164 (1.0) .012
Initial ventilator support>48 h, tracheostomy, or other pulmonary event 948 (5.4) 1039 (6.2) <.001
Atrial arrhythmia requiring treatment 1571 (9.0) 2287 (13.7) <.001
Ventricular arrhythmia requiring treatment 105 (0.6) 157 (0.9) <.001
Myocardial infarct 44 (0.3) 94 (0.6) <.001
Other cardiovascular event 260 (1.5) 360 (2.2) <.001
Gastrointestinal complications 288 (1.6) 447 (2.7) <.001
Postoperative blood transfusion 965 (5.5) 1127 (6.8) <.001
Bleeding requiring reoperation 109 (0.6) 158 (0.9) <.001
Urinary tract infection 390 (2.2) 225 (1.4) <.001
Empyema requiring treatment 45 (0.3) 98 (0.6) <.001
Wound infection 59 (0.3) 81 (0.5) .030
Sepsis or other infection requiring treatment 163 (0.9) 254 (1.5) <.001
New central neurologic event 90 (0.5) 112 (0.7) .045
Recurrent laryngeal nerve paresis or delirium tremens or other neurologic event 341 (1.9) 494 (3.0) <.001
New renal failure requiring treatment or worsening renal function (23 preoperative value) 171 (1.0) 343 (2.1) <.001
Chylothorax requiring drainage or medical treatment only 64 (0.4) 52 (0.3) .41
Chylothorax requiring surgical intervention 40 (0.2) 53 (0.3) .11
Other events requiring medical treatment or other events requiring OR with general
anesthesia or unexpected admission to ICU
758 (4.3) 1021 (6.1) <.001
DVT, Deep vein thrombosis; ICU, intensive care unit; OR, operating room.
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SIn general, our results are consistent with several other
studies of patients undergoing surgery for lung cancer. In
a study of patients undergoing lobectomy for lung cancer
in the STS Database,Wright and colleagues11 demonstrated
that male sex was an independent predictor of prolonged
length of stay after surgery. Rueth and colleagues,10 in an
analysis of 4171 patients from the national Surveillance
Epidemiology and End Results database, also reported
that male sex was an independent predictor of postoperative
pulmonary and cardiac complications. However, in contrast
to the findings reported by Rueth and colleagues, we found
that male sex was also predictive of noncardiopulmonary
complications. Some possible explanations for this could
be the fact that this study included patients with stage II,
III, and IV disease, or that the classification of noncardio-
pulmonary complications included more variables.
Having coronary artery disease was predictive of surgical
mortality in women but not in men. This may reflect
differences in the pathophysiology, disease spectrum,
clinical presentation, and management of coronary artery
disease in women.12 In addition to these differences,
it has been shown that the medical management and
evaluation of women with cardiovascular disease differ
from that of men.13,14 As a whole, women are referred for16 The Journal of Thoracic and Cardiovascular Surgecardiovascular diagnostic tests less often than men, which
may contribute to an underappreciation of disease extent
at the time of surgery.15 In addition, women with known
cardiovascular disease treated with aspirin prophylaxis
derive less protection against myocardial infarction than
men.16 It is also possible that practice patterns for thoracic
surgeons with regard to perioperative aspirin and beta-
blockade differ among women and men undergoing lung
resection; this has yet to be studied. In light of these find-
ings, it is important for the thoracic surgeon to optimize
medical management for all patients with known coronary
artery disease in the perioperative period to decrease the
risk of mortality. Current specialty guidelines, such as those
published by the American College of Cardiology, can be
helpful in this setting.17
For men but not women, thoracotomy as the surgical
approach and postoperative complications of prolonged
air leak and empyema were predictive of mortality.
These sex-based differences may be due to immunologic
differences between men and women in response to surgery
and physiologic stress. In studies of sepsis, women aged
more than 50 years had significantly lower hospital
mortality than their male counterparts.18 It has been
postulated that these differences can be attributed tory c July 2014
TABLE 3. Predictors of mortality after lung cancer resection
Variable
All patients
P value
Male
P value
Female
P valueOR (95% CI) OR (95% CI) OR (95% CI)
Female sex 0.56 (0.44-0.71) <.001
Age 1.06 (1.04-1.07) <.001 1.07 (1.08-1.09) <.001 1.04 (1.02-1.06) <.001
DLCO 0.98 (0.97-0.98) <.001 0.98 (0.97-0.99) <.001 0.97 (0.96-0.98) <.001
Coronary artery disease 1.23 (0.97-1.56) .095 1.09 (0.82-1.45) .54 1.64 (1.05-2.56) .035
Preoperative radiation therapy 1.60 (1.05-2.46) .033 1.86 (1.07-3.25) .03 1.24 (0.64-2.42) .53
Renal insufficiency 3.13 (2.09-4.68) <.001 2.80 (1.75-4.49) <.001 4.68 (2.19-10.04) <.001
Pathologic stage <.001 .007 .048
I 1.00 1.00 1.00
II 1.05 (0.76-1.44) 1.19 (0.82-1.73) 0.79 (0.42-1.49)
III 1.65 (1.24-2.21) 1.65 (1.14-2.38) 1.69 (1.04-2.74)
IV 2.43 (1.46-4.05) 2.53 (1.23-4.77) 2.19 (0.91-5.25)
Extent of resection <.001 <.001 <.001
Sublobar 1.00 1.00 1.00
Lobar 1.53 (1.07-2.19) 1.63 (1.03-2.60) 1.41 (0.80-2.48)
>Lobar 4.51 (2.95-6.89) 4.81 (2.82-8.22) 4.44 (2.18-9.05)
Approach .008 .65
Thoracotomy 1.00 1.00 .003 1.00
VATS 0.69 (0.52-0.91) 0.58 (0.40-0.85) 0.90 (0.58-1.41)
Postoperative air leak>5 d 1.33 (0.96-1.84) .096 1.58 (1.08-2.30) .023 0.88 (0.45-1.71) .69
Postoperative empyema 3.99 (1.88-8.45) .002 3.82 (1.68-8.65) .005 4.38 (0.55-34.72) .25
CI, Confidence interval; DLCO, diffusion capacity of carbon monoxide; OR, odds ratio; VATS, video-assisted thoracic surgery.
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mediators.19 Furthermore, it has been shown that patients
undergoing thoracoscopic lobectomy have decreased
immune suppression after surgery than those undergoing
thoracotomy.20-22 Because women have relatively less
immune suppression after surgery compared with men, it
is possible that the immunologic benefits of video-assisted
thoracoscopic surgery may be less significant for women.
Also, because immunosuppression is associated with
prolonged air leaks after thoracic surgery, it is conceivable
that women have relatively decreased immune suppression
after lung resection compared to men, and thus may benefit
in terms of fewer postoperative air leaks.23,24 This certainly
represents an area of possible future study.
In this study, pathologic stage, resection greater than
lobectomy, and postoperative empyema also were indepen-
dent predictors of surgical mortality. This is consistent with
other authors’ findings.25-27 However, in the current study,
decreasing FEV1 did not predict mortality. This is in
contrast to other studies, in which FEV1 has been
associated with surgical mortality.9,25
Study Limitations
Our study is potentially limited by missing data in the
STS General Thoracic Database. The initial study cohort
had 34,188 patients; however, because of missing data,
only 15,529 were included in the multivariable model.
Although the data remain robust, including the other
18,659 patients from the initial analysis might strengthen
the findings and conclusions in this study. In addition, theThe Journal of Thoracic and CSTS Database is a voluntary database of thoracic surgeons
and may not accurately reflect procedures performed by
nonparticipants or noncardiothoracic surgeons.
CONCLUSIONS
It has been demonstrated that women undergoing lung
cancer resection have improved long-term survival relative
to men.5,6,8 There are several points along the lung
cancer treatment continuum that can affect outcomes and
survival, including surgery and its postoperative
complications. Patients with increased morbidity from
surgery and prolonged hospital stays may take longer to
fully recover from the operation. As such, these patients
may be less likely to begin adjuvant therapy in a timely
manner, and therefore may not receive the optimum
benefit from this treatment. As we, and others, have
demonstrated that female sex is predictive of superior
postoperative outcomes, it is possible that these
differences contribute to the sex-related differences in
long-term survival. Although several factors such as age,
sex, stage, histology, and performance status are known to
influence long-term survival for patients with non–small
cell lung cancer, there is relatively little information
regarding the effect of perioperative outcomes on long-
term survival.28,29 Whether the sex differences in
perioperative outcomes influence the long-term survival
for patients with lung cancer remains to be seen. Additional
longitudinal studies of these sex differences, with particular
emphasis on completion and adherence to adjuvant therapy
regimens, would be helpful in this regard. Also, studies ofardiovascular Surgery c Volume 148, Number 1 17
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Stumor biology and response to therapy, as related to the
respective female and male physiologic states, might help
to provide answers to these important questions.
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